The Power of Genetic Testing for Hemophilia MLOF is open to all people with hemophilia A and B. Read More Novel Technologies Hemophilia Gene Therapy Comes of Age More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia. Read More Novel Technologies Unlocking Hemophilia The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia. Read More Novel Technologies Six at a Time Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6. Read More Novel Technologies FVII Gene Therapy Trial in Dogs; New FIX and HCV Drugs An update on FVII gene therapy and more. Read More Novel Technologies FDA in Action Updates on Daklinza, Technivie, and the ACE910 trial Read More Novel Technologies Recognizing Great Clinical Work NHF is committed to the training and support of clinician-researchers in hematology. Read More Researcher Profiles Announcing JGP Fellowship Recipients NHF awarded 5 JGP Fellowships in 2014. Read More Researcher Profiles Home Stretch There are times when less really is more. With the June 6, 2014, US Food and Drug Administration (FDA) approval... Read More Novel Technologies Wave of Progress Progress. For years, the bleeding disorders community has been waiting for meaningful progress for a greater understanding of hemophilia, for... Read More Novel Technologies, Hemophilia A&B CDC’s Inhibitor Risk Study A six-year study by the US Centers for Disease Control and Prevention (CDC) of patients with inhibitors, antibodies to infused... Read More Novel Technologies NHF-Shire Clinical Fellow Profile: Rachael Grace, MD, MMSc This interview was conducted with Rachael Grace, MD, MMSc, Director, Hematology Clinic, Boston Children’s Hospital. The fellowship was funded from... Read More Researcher Profiles Load More
